Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 4/20 | 0.75 |
| ▸ | CYCS | P99999 | 4/20 | 0.73 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | STAT1 | P42224 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15258312 | 0.96 | TOP1 (0.81) | TOP1CYCSENPP2ABCG2KDM4E | |
| SCHEMBL25394852 | 0.91 | TOP1 (0.91) | TOP1CYCSENPP2ABCG2STAT3 | |
| SCHEMBL483511 | 0.91 | TOP1 (0.91) | TOP1CYCSENPP2ABCG2STAT3 | |
| SCHEMBL16418477 | 0.91 | TOP1 (0.91) | TOP1CYCSENPP2ABCG2STAT3 | |
| SCHEMBL25395869 | 0.91 | TOP1 (0.91) | TOP1CYCSENPP2ABCG2STAT3 | |
| SCHEMBL29556585 | 0.91 | TOP1 (0.91) | TOP1CYCSENPP2ABCG2STAT3 | |
| SCHEMBL17934752 | 0.90 | TOP1 (0.60) | TOP1CYCSENPP2ABCG2STAT3 | |
| SCHEMBL19640818 | 0.90 | CYCS (0.91) | TOP1CYCSENPP2ABCG2STAT3 | |
| SCHEMBL6693557 | 0.90 | TOP1 (0.88) | TOP1CYCSENPP2ABCG2STAT3 | |
| SCHEMBL6686149 | 0.90 | TOP1 (0.88) | TOP1CYCSENPP2ABCG2STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3038619-B1 | COMPOUND AND METHOD FOR VACCINATION AND IMMUNISATION | PCI BIOTECH AS (NO) | 2023-10-04 | — | — | EP | disclosed |
| EP-3185901-B1 | COMPOUND AND METHOD | PCI BIOTECH AS (NO) | 2023-10-04 | — | — | EP | disclosed |
| US-20170252441-A1 | COMPOUND AND METHOD | PCI BIOTECH AS (NO) | 2017-09-07 | — | — | US | disclosed |
| US-20160206725-A1 | COMPOUND AND METHOD FOR VACCINATION AND IMMUNISATION | PCI BIOTECH AS (NO) | 2016-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170252441-A1 | COMPOUND AND METHOD | CSF3R, IL2, IL5 | TOP1 2013/4885CYCS 2836/4885ENPP2 226/4885 |
| US-20160206725-A1 | COMPOUND AND METHOD FOR VACCINATION AND IMMUNISATION | TLR9, TLR3, TLR1 | TOP1 3662/4885CYCS 4582/4885ENPP2 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.